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Resumen
Objetivo: Describir el conocimiento actual y el manejo del envejeci-
miento y la complejidad farmacoterapéutica en pacientes VIH +.
Método: Se realizó una revisión bibliográfica, incluyéndose artículos, origi-
nales o revisiones, publicados en lengua inglesa o española, desde 2007 al 
2017, que analizaron el envejecimiento y la complejidad farmacoterapéutica en 
pacientes VIH ≥ . Se combinaron los términos: “Polypharmacy”/“Polifarmacia”, 
“Aging”/“Envejecimiento”, “Frailty”/“Fragilidad”, “Complejidad Farmacotera-
péutica”/“Medication Regimen Complexity” y “HIV”/”VIH”. La revisión se 
realizó de forma independiente por dos autores. Se analizó el grado de 
concordancia según el índice Kappa.
Resultados: Se analizaron 208 referencias bibliográficas, incluyéndo-
se finalmente 68. Se ha identificado un envejecimiento de la población 
y un incremento de las comorbilidades asociadas, especialmente a partir 
de los 50 años. Se han descrito cambios inmunológicos similares a los 
que se generan en la población anciana no infectada. Esto condiciona, 
según estudios identificados, la prescripción del tratamiento antirretroviral. 
Paralelamente, el concepto de polifarmacia está cada vez más presente, 
definiéndose exclusivamente por el uso concomitante de cinco fármacos. 
La complejidad farmacoterapéutica, a través del Medication Regimen 
Complexity Index, se ha empezado a analizar y a relacionar con resulta-
dos en salud. Se ha evidenciado una necesidad de profundizar y aplicar 
conceptos ya conocidos en la población no VIH envejecida, como des-
prescripción, medicación potencialmente inapropiada, riesgo colinérgi-
co, etc., aunque existen pocos resultados disponibles.
Conclusiones: Existe un interés creciente en profundizar en la relación VIH 
y envejecimiento. La complejidad farmacoterapéutica está empezando a uti-
Abstract
Objective: To describe the current knowledge and management of 
aging and pharmacotherapeutic complexity in HIV + patients.
Method: A review of literature was carried out, including articles, originals 
or reviews, published in English or Spanish, from 2007 to 2017, which 
analysed the aging and pharmacotherapeutic complexity in HIV + patients. 
The terms «Polypharmacy»/«Polifarmacia», «Aging»/«Envejecimiento», 
«Frailty»/«Fragilidad», «Complejidad Farmacotera péutica»/«Medication 
Regimen Complexity» and «HIV»/«VIH» were combined. The review was 
carried out independently by two authors. The degree of agreement, accor-
ding to the Kappa index, was analysed.
Results: A total of 208 references were analysed, including, finally, 
only 68. An aging of the population and an increase in associated 
comorbidities have been identified, especially over 50 years-old. Immu-
nological changes similar to those that are generated in a non-infected 
elderly population have been described. These conditions influencing 
the prescription of antiretroviral treatment, according to studies identified. 
In parallel, polypharmacy is increasingly present, being defined exclusi-
vely by the concomitant use of five drugs. Pharmacotherapeutic comple-
xity, through the Medication Regimen Complexity Index, has begun to 
analyse and relate to health outcomes. There has been a need to know 
and apply concepts already known in non-HIV-aged population, such 
as deprescription, potentially inappropriate medication, cholinergic risk, 
although few results are available.
Conclusions: There is a growing interest to know about the relation-
ship between HIV and aging. Pharmacotherapeutic complexity is begi-
nning to be used as a pharmacotherapeutic follow-up criterion due to its 
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influence on health outcomes. It is necessary to manage and incorporate 
new concepts that help pharmacotherapeutic optimization in this pop-
ulation.
lizarse como criterio de seguimiento farmacoterapéutico por su influencia en 
los resultados en salud. Es necesario manejar e incorporar nuevos conceptos 
que ayuden a la optimización farmacoterapéutica en esta población.
Introduction
Human immunodeficiency virus (HIV) infection is now considered to be a 
chronic disease thanks to the striking decrease in mortality following the in-
troduction of highly active antiretroviral therapy (HAART) and the subsequent 
arrival of new more potent drugs with better dosage regimens1. Increased 
survival has led to the parallel ageing of the HIV-positive population. In fact, 
data on different cohorts of HIV-positive patients have already been publis-
hed in international studies, showing that more than 50% of the individuals 
in treatment were already more than 50 years old. It has been suggested 
that by 2030 this percentage will have increased2.
The aging of the population has led to an increase in a range of comor-
bidities. It is also known that these comorbidities have a greater prevalence 
and occur earlier in HIV-positive patients than in the general population. It 
has been estimated that aging will accelerate over the next 10 years3-6. Si-
multaneous with the increase in comorbidity, the concept of polypharmacy 
has gained increasing exposure in the setting of the increased prevalence 
of HIV-positive patients7, although, according to most authors, there is no 
consensus on its definition8. With the aim of providing a more accurate 
picture of pharmacotherapy, rather than a simply quantitative one, the term 
medication regimen complexity has been coined. Different tools are availa-
ble for its measurement, and its relationship with different health outcomes 
is already known9-12.
The experience and scientific evidence obtained with the general popu-
lation are already serving as a starting point for the assessment and mana-
gement of elderly patients with HIV13-16. However, knowledge and consen-
sus on many key factors is needed within the multidisciplinary teams caring 
for these patients, which would help to reorientate and improve healthcare 
in this population.
The objective of this review was to describe the current state of knowled-
ge and the management of aging and medication regimen complexity in 
HIV-positive patients.
Methods
A literature search was conducted using the following databases: Med-
line (via Pubmed), Scopus, Web of Science, the Cochrane Library, and 
Google Scholar.
Inclusion criteria were: all English- or Spanish-language original or 
review articles published between 2007 and 2017 which analysed the 
management of aging and medication regimen complexity in HIV-positive 
patients older than 50 years.
The Medline database was searched using Medical Subject Hea-
dings (MeSH), which is a thesaurus created by the US National Library 
of Medicine. The following English and Spanish terms were used in 
combination: “Polypharmacy”/“Polifarmacia”, “Aging”/“Envejecimiento”, 
“Frailty”/“Fragilidad”, “Complejidad Farmacoterapeutica”/“Medication Re-
gimen Complexity”, and “HIV”/”VIH”.
The articles were independently reviewed by two of the authors of this 
article. Disagreements were resolved by consensus. Inter-rater agreement on 
the inclusion of the selected articles was assessed using the Kappa index (a 
cutoff value of 0.80 was used to indicate good correlation).
Subsequently, we analysed and combined the data extracted from the 
articles that met the inclusion criteria.
Results
A total of 208 bibliographic references related to the study objectives 
were identified and analysed. Figure 1 shows the flowchart of the revised 
bibliography according to the inclusion and exclusion criteria used. Table 1 
shows the selected studies, which include data relevant to the setting of 
HIV-positive patients.
In general, polypharmacy has been defined as the concomitant and 
simultaneous use of multiple medications. However, the term has many de-
finitions, which include aspects such as the use of potentially inappropriate 
Figure 1. Flow Diagram of the Literature Review and Inclusion/Exclusion Process of the Studies Analysed.
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TABLE 1. Main Conclusions of the Original Articles on HIV+ Patients Included in the Review
AUTHORS-YEAR (REFERENCE) MAIN CONTRIBUTIONS
AGING AND FRAILTY
Deeks et al. 20093
Although mortality in HIV-positive patients continues to decrease, it is still higher than in the non-HIV 
population 
The risk of non-AIDS-based comorbidities, including cardiovascular disease, liver disease, and cancer, 
is higher in the HIV population than in the general population. 
Blanco JR et al. 20104
In the absence of specific guidelines on the management of elderly HIV-positive patients, specific strate-
gies need to be designed to optimize therapies in these types of patients. Clinical trials and pharmaco-
dynamic and pharmacokinetic studies are needed. 
Guaraldi G et al. 201120
The prevalence of polypharmacy among HIV-positive patients aged 41 to 50 years was similar to that 
among the non-HIV population aged 51 to 60 years. A low nadir CD4 count and prolonged exposure 
to ART is associated with increased comorbidity. 
Schouten J et al. 201421
Age-associated comorbidities (i.e., mainly cardiovascular, renal, and mental disease) are more preva-
lent in the HIV-positive patient. In these patients, permanent and residual inflammation are factors that 
contribute to these comorbidities. 
Smit M et al. 201522
In 2030, the percentage of patients older than 50 years will be much higher than at present. There will 
be a significant increase in the number of associated comorbidities and, in parallel, the prescription of 
associated drugs.
Choi AI et al. 200741 Black patients with HIV and diabetes have a 4- to 5-fold higher risk of decreased kidney function than that of the rest of the population.
Hasse B et al. 201147
This was one of the largest worldwide cohort studies. It confirmed that multimorbidity is a problem 
of the first magnitude in HIV-positive patients. Multimorbidity particularly includes diabetes mellitus, 
cardiovascular diseases non-AIDS malignancies, and osteoporosis. Their risk increased with older age 
in HIV-positive elderly patients. 
POLYPHARMACY AND NEW ASSOCIATED CONCEPTS
Gimeno-Gracia M et al. 20166
The amount of medication prescribed for comorbidities is higher in the elderly HIV-positive population 
than in the non-HIV+ population. 
In this population, the most frequently prescribed drugs are ACEIs, statins, antidiabetics, antithrombotic 
agents, and calcium channel blockers.
Edelman EJ et al. 20137
This study provides an algorithm for the optimization of pharmacotherapy in HIV-positive patients with 
polypharmacy. It provides a deeper perspective on reconciliation, toxicity, and the benefit-risk balance 
of prescriptions, and on prioritizing and planning in each patient.
Krentz HB et al. 20128 This study investigated pill burden in HIV-positive patients over an extended period of follow-up. It des-cribes the concomitant use of families of drugs and the more commonly prescribed drugs.
Nozza S et al. 201716
There are a high number of “unconventional” prescriptions for antiretroviral treatment in elderly HIV-
positive patients, due to the need for individualization caused by the concomitant prescription of drugs 
and the need to avoid relevant interactions.
Gleason LJ et al. 201318
Currently, the key factors in managing the HIV-positive patient are: to reduce therapeutic burden, adjust 
doses, raise awareness of the influence of interactions on therapeutic success, and establish methodolo-
gies for a systematic review of all prescribed medication. 
Marzolini C et al. 201123 Increased comorbidities and comedication in these patients increases the risk of relevant drug interactions. 
Holtzman C et al. 201124
Of a total of 3800 patients analysed during a 5-year observation period, 7.0% had at least 1 contrain-
dicated interaction: the main problems were the use of proton pump inhibitors, statins, and benzodiaze-
pines. 30.0% of patients more than 50 years of age had prescriptions for medicinal herbs and vitamin 
supplements.
Cuzin L et al. 201726 The highest prevalence of comorbidities, and the highest number of concomitant prescriptions, appears in long-term HIV-positive patients. 
Guaraldi G et al. 201727 The choice and prescription of ART is influenced by concomitantly prescribed drugs. Potential interac-tions decrease the use of single-tablet-regimen co-formulations in the older HIV-positive population.
Cantudo-Cuenca MR et al. 201435 Patients with more prescribed drugs have lower adherence to antiretroviral treatment.
Nachega JB et al. 201236 New approaches are needed to improve the measurement and assessment of adherence in older HIV-positive patients with co-morbidities and simultaneous prescriptions for ART.
Littlewood RA et al. 200838 Despite the success of ART, a large percentage of HIV+ patients continue to use alternative medicines (medicinal herbs, vitamin supplements, etc), which significantly interfere with therapeutic success.
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medications (PIMs), the underuse of medication, or therapeutic duplica-
tion. Different numerical cutoff points have been used in published studies, 
although most have defined polypharmacy as the use of 5 concomitantly 
prescribed drugs17,18. However, since the publication of the document on 
HIV and advanced age by the National AIDS Plan and the Spanish Society 
of Geriatrics and Gerontology in 2015, which included this definition, a 
consensus has emerged in Spain that patients are polymedicated if they 
simultaneously use 6 or more active principles. This definition will be used to 
correlate and compare future studies19.
Different studies have already demonstrated the relevance of the pro-
blem from a qualitative perspective. Guaraldi et al. (2011) were the first 
authors to show that more than 2 chronic comorbidities were more com-
mon in HIV-positive patients older than 50 years than in non-HIV-infected 
participants of the same age20. These data were confirmed by Schouten et 
al. in 201421. Furthermore, a modelling study by Smit et al. suggested that 
84% of HIV-infected patients would have more than 2 comorbidities by 
203022. Marzolini et al. published the first study to show that 50 years is 
the age at which HIV-positive patients need significantly more medication 
prescriptions, and that 20% of these patients are prescribed more than 4 
medications23. A cross-sectional analysis of American patients within the HIV 
Outpatient Study (HOPS) cohort showed that 95% of the patients older than 
60 years were polymedicated, which was due to concomitant medication 
in 73% of these patients24.
A recently introduced analogous concept is pill burden, which includes 
the number of medications and the number of pills. Zhou et al. were the first 
authors to discuss pill burden in HIV-positive patients25. The results showed 
that the median number of medications per participant was 8 (interquartile 
range [IQR]: 6-11). The median individual daily pill burden was 8 pills (IQR: 
5–15), which comprised 3 antiretrovirals (ARVs) (IQR: 2-5) and 6 non-ARVs 
(IQR: 3-12.5). The duration of antiretroviral treatment (ART) (for every 2 years 
in treatment) and more than 3 comorbidities was significantly associated 
with high pill burden (more than 10 pills per day). In a similar analysis in 
a French cohort, Cuzin et al. found that 62% of HIV patients older than 
50 years had comorbidities and 71% were receiving comedication26. In a 
Spanish study, Gimeno-Gracia et al. investigated the use of concomitant 
medication in HIV-positive patients compared to the general population. In 
descending order of frequency, the most commonly prescribed families of 
medications were angiotensin-converting enzyme inhibitors, antidiabetics, 
statins, antithrombotic agents, and calcium channel blockers6. It has been 
found that antiretroviral therapy (ART) strategies are also affected by po-
lypharmacy. Guaraldi et al. suggested that single-tablet-regimens strategies 
are less likely to be prescribed in patients with simultaneous prescriptions 
for several concomitant drugs because of the risk of drug-drug interactions, 
among other factors27. The Italian GEPPO cohort study also confirmed that 
ARV regimens in elderly HIV patients are tailored according to polyphar-
macy16.
Recently, attempts have been made to pass from the analysis of the 
qualitative aspects of polypharmacy, particularly in HIV patients, to its quan-
titative aspects by analysing numeric data that can subsequently be used to 
measure healthcare outcomes. This aspect was analysed in the Pharmacy 
Practice Model Summit 2011 document published by the American Society 
of Hospital Pharmacy (ASHP), which recommended that the pharmacothe-
rapeutic follow-up of patients should be conducted based on a patient 
medication complexity index (CI). The CI should include factors such as the 
severity of the disease, number of medications, and comorbidities28. Up to 
this point in time, Martin et al. (2007) had published the only CI, which 
was designed to assess ARVs9. This CI provided a score based on the 
weighting of 15 variables grouped into four main blocks: dosing schedu-
les, administration methods, special instructions, and required preparations. 
Since then, the University of Colorado has continued to develop the tool to 
simplify its calculation and extrapolate it to any other pathology. This project 
led to the development of the Patient-level Medication Regimen Complexity 
Index (pMRCI) and the Antiretroviral Medication Regimen Complexity Index 
(ARCI)10,11,29, which include scores ranging from 0.75 to infinity depending 
on the prescribed medication.
In a HIV-positive cohort, Metz et al. found that the pMRCI scores ranged 
from 2 to 67.5 (ARVs contributed approximately 25% to the total value)11. 
Several authors have analysed the relationship between CIs and different 
TABLE 1 (cont.). Main Conclusions of the Original Articles on HIV+ Patients Included in the Review
AUTHORS-YEAR (REFERENCE) MAIN CONTRIBUTIONS
Barry DT et al. 201140
The nonmedical use of opioids in HIV-positive patients in the USA was associated with being Hispanic, 
aged 40 to 44 years, alcohol use disorders associated with drug use, smoking, co-infection with hepati-
tis C, and chronic pain. 
McNicholl IR et al. 201751 PIP was identified in 54% and 63.0% of HIV+ patients more than 50 years of age using the STOPP and Beers criteria, respectively.
Casajús-Navasal A et al. 201853 The percentage of HIV-positive patients aged 50 years or more who take anticholinergic drugs was significantly higher on the ACB scale than on the ARS scale. 
TREATMENT REGIMEN COMPLEXITY
Martin S et al. 20079
This study presents an antiretroviral regimen complexity index scoring system. This comprehensive 
system includes aspects such as treatment scheme, administration methods, special instructions, and 
required preparations.
Metz KR et al. 201411
In a cohort of HIV+ patients in real-life treatment, the Patient-level Medication Regimen Complexity Index 
(pMRCI) score ranged from 2 to 67.5.
Antiretroviral treatment contributed around 25% to the pMRCI.
Zhou S et al. 201425
This study was the first to discuss and assess pill burden in HIV+ patients. The median number of medica-
tions per participant was 8 and the median individual daily pill burden was 8 pills.
Duration of ART and having more than 3 comorbidities was associated with high pill burden.
Monje Agudo P et al. 201430 A complexity index greater than 5 identifies patients at high risk of ART discontinuation.
Jiménez Galán R et al. 201631
Treatment complexity is a key factor in achieving health goals in HIV+ patients receiving treatment for 
dyslipidaemia.
The complexity index was significantly higher in patients who did not reach the target values for hyperli-
pidaemia.
Calvo-Cidoncha E et al. 201532
The addition of antihepatitis C therapy to antiretroviral treatment in HIV+ patients significantly increases 
treatment complexity and the incidence of blips in HIV viral load.
After introducing anti-HCV therapy in HIV+ patients, adherence to ART decreased.
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health outcomes. Monje-Agudo et al. found that a CI score of 5 marked the 
threshold above which patients had a higher risk of ART discontinuation30. 
Jiménez-Galán et al. analysed the relationship between medication comple-
xity and adherence with therapeutic objectives in HIV-positive patients with 
dyslipidaemia. They found that although most patients met the objectives 
for ART, almost half of them did not meet the therapeutic objectives of dys-
lipidaemia treatment, especially those with a higher CI31. Calvo-Cidoncha 
et al. confirmed that the addition of antihepatitis C therapy to ART in HIV-
hepatitis C virus (HCV) co-infected patients led to an increase in medication 
regimen complexity and the risk of blips, and a decrease in adherence to 
ART32.
Clearly, patient treatment adherence is one of the main aspects to con-
sider regarding the repercussions of medication regimen complexity. Adhe-
rence has already been investigated in general population studies, whose 
results are of interest because of their possible relevance to the HIV-positive 
population33. A recent systematic review showed that a lack of adherence 
was associated with polypharmacy12. Although some of these studies su-
ggested that adherence rates tend to be better in older HIV-positive patients 
than in younger individuals, it has been observed that cognitive deteriora-
tion can hinder this objective. In addition, polypharmacy can contribute 
to regimen fatigue34. The study conducted by Cantudo-Cuenca et al. in 
the HIV-positive population showed that the concomitant use of medication 
decreases adherence to ARVs35.
Another factor highlighted in the literature is the risk of drug interac-
tions, which can be seen to increase in older HIV-positive patients due to 
treatments for multiple comorbidities that appear in this population (36-38). 
Furthermore, it is already known that most ARVs and other commonly used 
medications share a metabolic pathway at the level of cytochrome P450 
and P-glycoprotein39.
Polypharmacy and its impact on interactions have been described in 
studies such as that by Holtzman et al. in an American cohort of HIV-infec-
ted outpatients24. Slightly more than 3800 patients were analysed over a 
5-year observation period. Of these patients, 7% were prescribed at least 1 
contraindicated ARV/non-ARV combination. The main contraindicated non-
ARVs were proton pump inhibitors, statins, and benzodiazepines. Another 
key finding of this study was that almost 30% of HIV patients older than 50 
years were using medicinal herbs, vitamins, and other supplements that can 
interact with ARVs, as shown in other studies40-44.
In clinical terms, a basic issue has been to identify how the medica-
tion combinations used to treat chronic diseases and ART in older HIV-
infected adults increases the risk of clinically relevant interactions which 
can lead to the loss of drug efficacy, virological failure, and toxicity. It 
has been found that older patients are more susceptible to interactions 
than younger individuals19. Firstly, older patients have more age-related 
comorbidities. Secondly, age-related physiological changes affect the 
pharmacokinetic and pharmacodynamic properties of medications. The-
se physiological changes, which are also seen in HIV-positive patients, 
can be explained by a set of factors that include the patient’s genetics, 
lifestyle, and specific environment. Age-related pharmacokinetic chan-
ges are due to changes in the body mass index and in the functioning 
of organs that eliminate medications. Older age is associated with de-
creased hepatic volume and hepatic blood flow19, as well as creatinine 
clearance, leading to the decreased elimination of medications and thus 
their accumulation. The glomerular filtration rate decreases by about 1% 
per year as age increases. Current methods to estimate renal function 
may lead to it being overestimated in older adults if low muscle mass is 
not taken into account45-46. This problem is further complicated in HIV-in-
fected adults because they typically have less muscle mass than non-HIV-
positive adults. Another aspect to consider is that renal function can also 
be decreased by other pathologies or factors that act as confounders, 
such as diabetes mellitus, hypertension, low CD4 cell count, race, and 
the use of ARVs47-48. Thus, the estimation of renal function is more difficult 
in HIV-infected older adults, and affects the dosage and prescription of 
drugs excreted by the kidneys19.
Frailty is another key concept of increasing relevance in the management 
of HIV patients. It is an emerging syndrome which has been shown to be 
a good predictor of worse health status and adverse events in the gene-
ral population13,14. Frailty embodies a biological syndrome of diminished 
functional reserves, altered homeostatic capacity, and reduced resistance 
to external stressors. It is the result of an accumulation of deficiencies in phy-
siological systems and increases vulnerability to various adverse outcomes, 
including falls, delirium, hospitalization, disability, and death15. It is known 
that HIV-positive patients experience immune changes similar to those cau-
sed by aging in the uninfected elderly population. These changes occur as 
a result of a baseline state of immune activation and persistent inflammation 
that gradually lead to the premature aging of the immune system known as 
immunosenescence48. Chronic activation of the immune system is marked 
by persistent viral replication in reservoirs, coinfections with other viruses, 
and particularly by bacterial translocation due to persistent alteration of the 
intestinal barrier48.
These aspects have led to the new concept of “potentially inappropriate 
medications” (PIMs)49. Their use involves the risk of patients experiencing ad-
verse events which outweigh the clinical benefits of the PIMs, particularly in 
settings in which there are safer and more effective therapeutic alternatives. 
PIMs also include medications that are used more frequently or for a longer 
duration than indicated, the use of medications with a high risk of drug-drug 
interactions, the duplication of medications of the same class, the incorrect 
selection of the drug or dose, and the non-use or underuse of beneficial 
medications that are clinically indicated.
In the last decade, there has been growing interest in developing 
criteria to define the appropriateness of pharmacological treatment in 
the elderly. Different groups of criteria have been developed for the 
detection of PIMs in elderly patients, such as the Beers criteria and the 
Screening Tool of Older Person’s Prescriptions/Screening Tool to Alert 
doctors to Right Treatment (STOPP/START) criteria50. The application of 
these criteria to improve the use of medicines and avoid the use of PIMs 
in the HIV-positive population has been investigated and validated in se-
veral studies. McNicholl et al. recently identified potentially inadequate 
prescribing (PIP) in 54% and 63% of HIV-positive patients older than 50 
years, using the STOPP and Beers criteria, respectively51. Although the 
study by Greene et al.52 used a smaller sample than the previous study, 
it provided the first hints of aspects such as PIMs. PIMs were assessed 
by applying the Beers criteria, which includes a guide list of medication 
and classes of medications that should be avoided in patients older than 
65 years. Likewise, so-called anticholinergic risk was assessed using the 
validated anticholinergic risk scale (ARS) scale. This instrument is scored 
on a scale ranging from 0 to 3, where 3 indicates high risk and 0 indi-
cates no risk. The highest scores predicted a high risk of falls and mental 
disorders in the elderly population. The study found that 52% of patients 
were receiving PIMs and 17% had an anticholinergic risk score of 3. In 
real-world clinical practice, Casajús-Navasal et al. used the anticholi-
nergic burden (ACB) scale and ARS scale to measure anticholinergic risk 
in a cohort of Spanish patients older than 50 years old. In total, 43.3% 
and 36.4% of patients had high anticholinergic risk on the ACB and ARS 
scales, respectively53.
Deprescribing is a concept that is well known in the setting of the HIV-
negative elderly population54-57. Scott et al.58 defined it as the systematic 
process of identifying and discontinuing medications in cases in which cu-
rrent or potential harm outweighs current or potential benefit within the set-
ting of individualized healthcare that takes into account the patient’s current 
level of functioning, life expectancy, values,  and preferences. This process 
of drug withdrawal has the potential benefit of reducing the harmful effects 
associated with polypharmacy, while ensuring the ability of the patient to 
continue receiving the most appropriate therapy59. Studies have identified 
several barriers to reducing the number of medications and to facilitating 
deprescribing60,61. Currently, there is a wealth of information on when to 
start a therapy, including in the HIV-positive patient, but there is very little on 
how and when to stop it. Despite a lack of evidence in support of therapy 
being continued, the literature typically describes the continuation of the 
prescribed treatments60,61.
These new approaches to the management of medication derive from 
the concept of optimization of pharmacotherapy and the inclusion and 
application of these new concepts. This has led to a consensus on the need 
to review all prescribed medications at least every 6 months in elderly HIV-
positive patients who have been prescribed 4 or more medications, and 
at least once a year in the remaining patients19. An emerging priority is to 
identify and establish strategies to reduce medication regimen complexity 
and avoid polypharmacy in elderly HIV-positive patients to the greatest ex-
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tent possible. It is recommended that the review of prescribed medications 
should be conducted in a systematic manner using a sequential and struc-
tured methodology. Tables 2 and 3 show recommendations extracted from 
the literature on optimizing prescription strategies and introducing a review 
of polypharmacy in daily clinical practice.
Discussion
The management of HIV-positive patients, especially elderly ones, is of 
growing concern, as shown by the increasing number of articles addres-
sing this problem in recent years. However, we need to deepen our un-
derstanding of the new concepts and to confirm the results based on them, 
given that the definitions used, particularly those of polypharmacy and 
medication regimen complexity, and the comparative analysis methodo-
logy applied have not yet been standardised. Additionally, these new 
concepts, which have been identified as challenges by the professionals 
that serve this population, require a refocusing on care management in 
all professional settings. A priority issue is to avoid an exclusive focus on 
the treatment of the infection and the management of ARVs (adherence, 
interactions, and adverse effects). The literature analysed shows an incre-
asing number of emerging problems associated with aging, such as the 
management of comorbidities and functional and cognitive impairment. 
Furthermore, the physiological changes associated with aging must be 
taken into account in order to optimize pharmacotherapy and the clinical 
monitoring of these types of patients. According to the literature, such 
changes are not linear or consistent. Therefore, a global approach is 
needed that can identify elderly HIV-positive individuals, who are at risk 
of aging with a worse state of health or, equivalently, who are at risk of 
having a worse quality of life. The first available data on the application 
of these concepts in the older non-HIV population confirm a high rate of 
PIPs and elevated severe anticholinergic risk.
No study has addressed deprescribing in this population, but given the 
results published by various authors, a strategy is needed to implement this 
strategy and to measure its usefulness.
The main limitations found in the analysis were the use of different po-
pulations, age thresholds, and study methodologies. Similarly, the different 
definitions used and their lack of standardization make it difficult to compare 
different studies that have addressed similar concepts, especially polyphar-
macy and medication regimen complexity.
Future studies will confirm how the approach proposed by some authors 
will lead to a new vision of these patients and their management. Evidence 
is already urgently needed that would demonstrate that this new way of un-
derstanding the pathology leads to improvements in the health setting and in 
the patients themselves, given that such evidence is not currently available.
In conclusion, there is a growing interest in deepening our understanding 
of the relationship between HIV infection and aging. Medication regimen 
complexity is beginning to be used as a criterion for pharmacotherapeutic 
follow-up because of its influence on health outcomes. New concepts have 
to be incorporated and applied that will improve pharmacotherapeutic op-
timization in this population.
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Table 2. Ten Key Recommendations to Improve Pharmacological Prescription in HIV+ Patients
10 Key Recommendations
1. Review the medication periodically. Discuss and agree on changes with patients. Inform patients of the pharmacotherapeutic treatment aims.
2. Suspend all non-indicated medications.
3. Prescribe medication only if there is a clear indication.
4. Avoid potentially dangerous drugs in older patients.
5. Review and adjust the recommended doses according to liver and kidney function.
6. Simplify the treatment regimen and reduce treatment complexity.
7. Avoid or eliminate unnecessary pharmacological treatments.
8. As far as possible, limit the number of prescribers.
9. Identify, prevent, and manage adverse reactions.
10. Avoid prescription cascades.
Table 3. Recommendations on Introducing Medication Review in Daily Clinical Practice
Recommendations
1. Prioritize and establish medication review in selected patients with several clinical problems, polypharmacy, or high treatment complexity.
2. Implement a program and strategy of continuous and complete medication review for all patients, with greater focus on patients with 
greater complexity.
3. Include institutionalized patients.
4. Start the treatment process review in multidisciplinary meetings.
5. Define and agree on functions within the healthcare team in order to conduct a complete treatment review with permanent communication.
6. Periodically repeat the polypharmacy and treatment regimen complexity review according to the characteristics of each type of patient.
7. Apply, know, and, when appropriate, share the criteria for de-prescribing based on the Beers or STOP-START recommendations, 
anticholinergic risk, and potentially inappropriate medication.
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